Chemical Computing Group Releases MOE Version 2002.03 at Spring 2002 National ACS Meeting
MONTREAL, April 8, 2002
Chemical Computing Group (CCG) announced the latest release of its Molecular Operating Environment (MOE) at the Spring 2002 National Meeting of the American Chemical Society in Orland, FL. MOE is a comprehensive software system for Life Science researchers that integrates Bioinformatics,Cheminformatics and Molecular Modeling.
The new version, MOE 2002.03, is the result of CCG's continuing research and development program and includes important new capabilities:
Paul Labute, President and CEO of CCG said,
"In order to maximize research efforts, pharma and biotech companies need an integrated Life Science software platform and CCG is taking on this challenge."He went on to say that,"This release of MOE is an important milestone in our development. From a scientific application perspective, MOE now contains comprehensive coverage of Bioinformatics, Cheminformatics, High Throughput Discovery, Structure-Based Design, Protein Modeling and Molecular Modeling. From an information technology perspective, MOE integrates User Interface, Scientific Discipline, Platform Independence and Distributed Computing in one system thereby facilitating a smoother flow of information."
Bill Hayden, Vice President - Sales & Marketing added,
"For the first time, Life science companies will be able to deliver high-end computational methodology throughout their organizations. Information and ideas can now be shared between biology, medicinal chemistry and computational groups. By allowing researchers from various parts of the organization to interact with each other more easily, research efforts can be optimized and the return on the research dollar invested by the company increased."
ABOUT CCG:
Chemical Computing Group (http://www.chemcomp.com) develops and
markets MOE, the Molecular Operating Environment, a leading
application for chemical researchers in the pharmaceutical and
biotechnology fields. Its built-in applications cover the spectrum
of drug discovery including: Protein/Homology modeling, High
Throughput Screening, Combinatorial Library Design,
Modeling/Simulations and Methods Development. MOEs unique
architecture and platform independence allows it to be used
corporate-wide by a variety of researchers - from methods
developers to computational experts to medicinal chemists. Its
customers include a worldwide roster of leading pharmaceutical and
biotechnology companies.